| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01384591 | Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly | PHASE1 | COMPLETED | 6 | — | — | Jul 1, 2011 | May 1, 2015 | May 8, 2018 | 1 | United States |
Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.
| Arm | Type | Description |
|---|---|---|
| Losartan and placebo N-acetylcysteine | EXPERIMENTAL | losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2. |
| Placebo losartan and placebo N-acetylcysteine | PLACEBO_COMPARATOR | Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2. |
| N-acetylcysteine and placebo losartan | EXPERIMENTAL | N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2. |
| Name | Type | Description |
|---|---|---|
| N-acetylcysteine | DRUG | 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2. |
| Losartan | DRUG | 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2. |
| Placebo losartan | DRUG | Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2. |
| Placebo N-acetylcysteine | DRUG | Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2. |
Inclusion Criteria: 1. Age between 60-85 years. 2. Ability to sign informed consent. 3. Ability to sign consent form. 4. Ability to pass a mini-mental status exam (score \>23 on the 30-item Mini Mental State Examination, MMSE). 5. Free-living, prior to admission. Exclusion Criteria: 1. Subjects w...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Boston Scientific Corporation | BSX | 1 | NA | Undisclosed |
| HeartFlow, Inc. | HTFL | 1 | NA | Rosuvastatin |
| Ultragenyx Pharmaceutical, Inc. | RARE | 1 | — | Undisclosed |